Dr. Guo-Liang Yu is a co-founder of CBT Pharmaceuticals, Inc. and serves as the the Chairman of the Board. Dr. Yu is a venture partner at Orbimed Venture LLC and the Executive Chairman of Crown Bioscience Inc. Dr. Yu co-founded Epitomics Inc., an antibody based Biotechnology Company recently acquired by Abcam at $170 M. He served as Chairman, President and CEO of Epitomics Inc. for 10 years. Dr. Yu’s success is driven by his scientific curiosity and a passion for translating scientific discovery to real products. His challenge is to balance his time between science and business, fun and work, family and community.
He moved from China to the US to pursue advanced training after graduating from Fudan University in 1984. He obtained his PhD from UC Berkeley where he contributed to the discovery of telomerase and its mechanism of action in Dr. Blackburn’s lab. Drs. Blackburn and Greider received the Nobel Prize in 2009 for their discovery. After graduating, Dr. Yu joined Dr. Frederick Ausubel’s lab at Harvard to pursue the question of how plants defend themselves against pathogens without an immune system. He identified the first plant disease resistance gene.
A co-founder and Senior Managing Director of OrbiMed Asia, Dr. Wang has over 20 years of healthcare and life sciences experience, spanning investment, entrepreneurship， finance and research. He has been named one of the top 10 healthcare investors in China (ChinaVenture). Previously, he held leadership positions at Burrill and WI Harper. He was or is a Board Director at a number of companies, including ForteBio (acquired by Pall Corporation), EA and Genewiz.
He is a co-founder and former Chairman of BayHelix, a premier organization of Chinese healthcare business leaders. Under the supervision of Eric Kandel, a Nobel Laureate, Dr. Wang obtained a PhD in Molecular Neurobiology from Columbia University. He was rewarded the Howard Hughes Medical Institute (HHMI) Research Fellowship at Columbia. He also earned an MBA from Stanford University.
Dr. Sanjeev Redkar is a co-founder of CBT Pharmaceuticals, Inc. that was started as a spin-off in early 2016. In his previous role, Dr. Redkar was the Senior Vice President of Product Development at Astex Pharmaceuticals, an Otsuka company, responsible for pharmaceutical development, technical operations and manufacturing. Dr. Redkar has been closely involved in preclinical and clinical development as well as global launches of several drugs including Dacogen and Nipent.
Dr. Redkar is a co-inventor of guadecitabine, a novel hypomethylating agent now in Phase 3 clinical trials. He has over 20 years of oncology drug development experience and has several peer-reviewed publications and patents. Dr. Redkar earned his doctorate from the University of Colorado, Boulder, a MBA from St. Mary’s College of California, and an undergraduate at the Indian Institute of Technology, Bombay. Dr. Redkar is an Adjunct faculty and a Board Member at the University of the Pacific School of Pharmacy, Stockton and Chairman of the Board of EPPIC, a pharmaceutical professional’s network.